retatrutide clinical trial results 2025 The Dosage Chart The MariTide phase 2 trial

Description

34 A 72-week Phase 2 clinical study was performed using Semaglutide to evaluate the efficacy and safety of three different doses of subcutaneous administration versus placebo in 320 subjects with biopsy-confirmed NASH and liver fibrosis stages 1, 2 or 3 (ClinicalTrials.gov NCT02970942)

Obesity has multiple negative effects on pulmonary function due to the physical forces of extra weight on the lungs and inflammation related to adipose tissue (see Figure 1) (Zerah et al

(2) reduce clearance rate due to slowed metabolism and renal filtration (131)

24, Dec

Real World Impact: Current Use and Outcomes These medications are no longer niche, they're influencing population level trends: Rapid Growth in Use In the U.S., reported use of GLP-1 weight loss drugs has more than doubled in the past year, from about 5.8% of adults in early 2024 to over 12% in 2025 Women tend to use these medications at higher rates than men, with 15.2% vs